Hjm Groen

Phase I and pharmacokinetic study of the topoisomerase II catalytic inhibitor fostriecin.

H. Groen, P. Willemse, D. Sleijfer, 1999, British journal of cancer.

A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer.

E. Smit, P. Postmus, H. Groen, 1998, British Journal of Cancer.

Continuous carboplatin infusion during 6 weeks' radiotherapy in locally inoperable non-small-cell lung cancer: a phase I and pharmacokinetic study.

H. Groen, N. Mulder, E. de Vries, 1995, British Journal of Cancer.

Irradiation of rat brain reduces P-glycoprotein expression and function

W. V. D. Graaf, R. Coppes, Hjm Groen, 2007, British Journal of Cancer.

Broad phase II and pharmacokinetic study of methoxy-morpholino doxorubicin (FCE 23762-MMRDX) in non-small-cell lung cancer, renal cancer and other solid tumour patients.

H. Groen, J. Verweij, A. V. van Oosterom, 1998, British Journal of Cancer.

Randomized comparison of etoposide pharmacokinetics after oral etoposide phosphate and oral etoposide.

H. Groen, N. Mulder, E. de Vries, 1997, British Journal of Cancer.

A phase I study with MAG-camptothecin intravenously administered weekly for 3 weeks in a 4-week cycle in adult patients with solid tumours

H. Groen, J. Maring, A. V. van Oosterom, 2004, British Journal of Cancer.